<?xml version="1.0"?>
<Articles JournalTitle="International Journal of Hematology-Oncology and Stem Cell Research">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>International Journal of Hematology-Oncology and Stem Cell Research</JournalTitle>
      <Issn>2008-2207</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="epublish">
        <Year>2020</Year>
        <Month>01</Month>
        <Day>01</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">Evaluation of CD160 and CD200 Expression as Differentiating Markers between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms</title>
    <FirstPage>27</FirstPage>
    <LastPage>37</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Wafaa</FirstName>
        <LastName>El- Neanaey</LastName>
        <affiliation locale="en_US">Department of Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Rania</FirstName>
        <LastName>Swelem</LastName>
        <affiliation locale="en_US">Department of Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Omar</FirstName>
        <LastName>Ghallab</LastName>
        <affiliation locale="en_US">Department of Internal Medicine (Hematology), Faculty of Medicine, University of Alexandria, Alexandria, Egypt</affiliation>
      </Author>
      <Author>
        <FirstName>Sara</FirstName>
        <LastName>Abu-Shelou</LastName>
        <affiliation locale="en_US">Department of Clinical and Chemical Pathology, Faculty of Medicine, University of Alexandria, Alexandria, Egypt</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2019</Year>
        <Month>05</Month>
        <Day>14</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2019</Year>
        <Month>09</Month>
        <Day>02</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Background: The present work aimed to investigate the expression of CD160/ CD200 in CLL and other mature B-cell neoplasms (MBN) and their use as an additional diagnostic tool for differentiating CLL from other MBN.
Materials and Methods: Using flowcytometry, we detected the expression of CD160 &amp;CD200 on B-cells from 30 CLL patients, 30 other MBN patients in addition to 20 controls. CDs160/200 measurements were determined as a percentage expression (&#x2265;20% was considered positive) and as a ratio of the mean &#xFB02;uorescence intensities (MFIR) of leukemic cells/controls and were considered positive when the ratios were &#x2265;2 and 20, respectively.
Results: 90% and 100% of the CLL group expressed CDs160/200 in comparison to 60% and 63.3% of other MBN (p=0.007, p&lt;0.001) respectively. By MFIR; 96.7% and 50% of our CLL group expressed CDs160/200 in comparison to 76.7% and 30% of other MBN, respectively. CDs160/ 200 were not expressed on the controls. Positive co-expression of CD160 and CD200 was found in 90% of the CLL cases, 60% of HCL patients &amp; only in 40% of B-NHL. However, double negative expression of both markers was found only in 24% of the B-NHL patients.
Conclusion: CD160 with CD200 can be used as additional diagnostic markers to the available routine panel to differentiate between B-CLL &amp; other non-specified B-NHL patients.
&#xD;

&#xA0;</abstract>
    <web_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1131</web_url>
    <pdf_url>https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1131/809</pdf_url>
  </Article>
</Articles>
